These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19398459)

  • 1. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
    Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
    J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
    Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
    J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and biodistribution studies of amphotericin B microspheres.
    Angra PK; Siddig A; Nettey H; Desai N; Oettinger C; D'Souza MJ
    J Microencapsul; 2009 Nov; 26(7):627-34. PubMed ID: 19839798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
    Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
    Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
    Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
    Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
    J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the toxicity of a new lipid complex formulation of amphotericin B.
    Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
    J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
    Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
    Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
    Kaur K; Kumar P; Kush P
    Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
    Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
    Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma.
    Henderson RJ; Leon CG; Wasan KM
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
    Matsui S; Imai S; Yabuki M; Komuro S
    Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B.
    Jain S; Valvi PU; Swarnakar NK; Thanki K
    Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model.
    Qu L; Li L; Xie H
    Ophthalmic Res; 2010; 43(3):153-8. PubMed ID: 19887881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Int J Pharm; 2012 Oct; 436(1-2):318-23. PubMed ID: 22772485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.